Regeneron, Sanofi arthritis drug may only help critical coronavirus patients - study

(Reuters) - Results of a study of Regeneron Pharmaceuticals Inc and Sanofi SA's rheumatoid arthritis drug Kevzara indicate it may only help the sickest coronavirus patients, the companies said on Monday, dampening hopes the medicine could benefit a wider group of those infected.The drugmakers said they would continue to test high doses of Kevzara only in those who are considered critically ill with COVID-19, the disease caused by the highly contagious virus. The decision was based on guidance..